Health disparities experienced by Black Americans with multiple myeloma in the United States: A population-based study.

Authors

Samer Al Hadidi

Samer Al Hadidi

Baylor College of Medicine, Houston, TX

Samer Al Hadidi , Deepa Dongarwar , Hamisu Salihu , Rammurti T. Kamble , Premal D. Lulla , LaQuisa Hill , George Carrum , Carlos Almeida Ramos , Helen E. Heslop , Saad Zafar Usmani

Organizations

Baylor College of Medicine, Houston, TX, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, Levine Cancer Institute/Atrium Health, Charlotte, NC

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health

Background: Multiple Myeloma (MM) is the most common hematologic malignancy in Black Americans. Incidence and death rates for MM in Black Americans are more than double those in Whites. Our study aimed to evaluate trends of all cause in-hospital mortality among Black Americans with MM and to investigate characteristics of MM-related hospitalizations. Methods: We conducted a retrospective cross-sectional study of hospitalizations in adult patients with MM during 2008-2017 using the National Inpatient Sample (NIS), the largest all-payer inpatient care database in the US. We used joinpoint regression to assess temporal trends in the national incidence of in-hospital death. We conducted adjusted survey logistic regression to generate adjusted odds ratios to measure the likelihood of in-hospital death among MM related hospitalizations. Results: Admissions related to MM constituted 0.32% of all hospitalizations in the study period (913,967 out of 285,876,821). The prevalence of MM related hospitalizations was higher in Black Americans when compared with Whites (476.0 vs 305.6 per 100,000 hospitalizations, p <0.01). In-hospital mortality with MM was higher in older patients, males, those belonging to lowest zip code quartile, and who self-paid for their treatment. Average Annual Percent Change (AAPC) showed a statistically significant decline of in-hospital mortality among all MM patients except Black Americans who had the highest inpatient mortality in 2016 and 2017. Black Americans received less autologous stem cell transplantation (ASCT) (2.8% vs. 3.8%, p <0.01), more blood product transfusions (23.0% vs. 21.1%, p <0.01), less palliative care consultation (4.0% vs. 4.6%, p <0.01), less chemotherapy (10.8% vs. 11.2%, p <0.01), and more intensive care utilization (5.3% vs. 4.3%, p <0.01), when compared with Whites. Adjusted association between race/ethnicity and various outcomes confirmed observed differences [Table]. Conclusions: Black Americans with MM had the slowest improvement and highest inpatient mortality in recent years. Data suggests higher disease burden, more frequent hospitalizations, delay in accessing care and lower utilization of supportive care measures compared with White MM patients. Data highlight disparities in MM care for Black Americans necessitating a clarion call for urgent changes in health care systems.


OR (95% CI)
P-value
In-hospital death

White

Black

Hispanic


Ref

1.02 (0.96-1.08)

0.99 (0.9-1.08)




0.5

0.74
ASCT

White

Black

Hispanic


Ref

0.68 (0.58-0.79)

0.91 (0.74-1.12)




< 0.01

0.38
Blood product transfusion

White

Black

Hispanic


Ref

1.12 (1.06-1.18)

1.01 (0.92-1.1)




< 0.01

0.9
Chemotherapy use

White

Black

Hispanic


Ref

0.91 (0.84-0.98)

1.04 (0.92-1.18)




0.02

0.52
Palliative care consultation

White

Black

Hispanic


Ref

0.91 (0.85-0.97)

0.83 (0.75-0.93)




0.01

< 0.01
ICU utilization

White

Black

Hispanic


Ref

1.24 (1.17-1.32)

1.00 (0.91-1.11)




< 0.01

0.95

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Access to Care

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr e18512)

DOI

10.1200/JCO.2021.39.15_suppl.e18512

Abstract #

e18512

Abstract Disclosures

Similar Abstracts